These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 18448339

  • 1. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
    Naud J, Lemke C, Goudreau N, Beaulieu E, White PD, Llinàs-Brunet M, Forgione P.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3400-4. PubMed ID: 18448339
    [Abstract] [Full Text] [Related]

  • 2. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, Lindström S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6189-93. PubMed ID: 18954982
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
    Bilodeau F, Bailey MD, Bhardwaj PK, Bordeleau J, Forgione P, Garneau M, Ghiro E, Gorys V, Halmos T, Jolicoeur ES, Leblanc M, Lemke CT, Naud J, O'Meara J, White PW, Llinàs-Brunet M.
    Bioorg Med Chem Lett; 2013 Jul 15; 23(14):4267-71. PubMed ID: 23735741
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D.
    J Med Chem; 2004 Mar 25; 47(7):1605-8. PubMed ID: 15027850
    [Abstract] [Full Text] [Related]

  • 5. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 25; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
    Perni RB, Farmer LJ, Cottrell KM, Court JJ, Courtney LF, Deininger DD, Gates CA, Harbeson SL, Kim JL, Lin C, Lin K, Luong YP, Maxwell JP, Murcko MA, Pitlik J, Rao BG, Schairer WC, Tung RD, Van Drie JH, Wilson K, Thomson JA.
    Bioorg Med Chem Lett; 2004 Apr 19; 14(8):1939-42. PubMed ID: 15050632
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX, Njoroge FG.
    Prog Med Chem; 2010 Apr 19; 49():1-36. PubMed ID: 20855037
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Madison V, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2151-5. PubMed ID: 20226659
    [Abstract] [Full Text] [Related]

  • 15. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM, Carey SJ, Chaignot H, Coomber BA, Gray NM, Hind SL, Jones PS, Mills G, Robinson JE, Slater MJ.
    Org Lett; 2002 Dec 12; 4(25):4475-8. PubMed ID: 12465916
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
    Nair LG, Bogen S, Ruan S, Pan W, Pike R, Tong X, Cheng KC, Guo Z, Doll RJ, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1689-92. PubMed ID: 20149655
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7317-22. PubMed ID: 21067923
    [Abstract] [Full Text] [Related]

  • 20. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.